Summary
54 / 100 · Bulios Score
What speaks for it
- Revenue grew by 30% a year over the last 3 years.
What to watch
- Repaying its net debt would take 6.4 years of operating profit.
- It missed profit estimates 4 times in the last 7 quarters.
- It earns only 6.1 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedToday you pay 27.0 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 30% a year over the last 3 years. Earnings per share grew by 6.9% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 80 USD
- Sales and administration 12 USD
- Taxes and other 2.5 USD
- Net profit 4.8 USD
Net profit, industry median (Medical - Care Facilities) 6.7 USD
Out of every 100 USD of revenue, 4.8 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 7.1 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 8
- Hold 0
- Sell 0
Today's price within the analysts' price targets
The average target of $56.67 is 24% above today's price. 100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Reportable Segment 100%
By region
The company reports no revenue by region.
Reportable Segment brings in 100% of revenue.
Segments in detail